The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
Recruitment for a verteporfin trial and a separate hair cloning trial using verteporfin and other methods is underway, with locations in Jordan, NYC, Beverly Hills, and Memphis. Dr. Bloxham is conducting the hair cloning trial, and interested participants are encouraged to contact him directly.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
A new company is introducing a topical treatment combining Minoxidil, Finasteride, and Bimatoprost for hair loss. Users are also inquiring about updates on a minoxidil-enhancing shampoo from Applied Biology.
The conversation is about using topical melatonin for hair retention and its potential effectiveness alongside minoxidil. The user explicitly does not want advice about finasteride.
A 20-year-old is concerned about hairline changes and wonders if it's maturing or male pattern baldness (MPB). Suggestions include consulting a specialist and considering treatments like finasteride or minoxidil.
The user experienced significant hair regrowth in two months using finasteride, topical minoxidil, and weekly microneedling, but developed dark spots on the scalp, possibly from irritation. They plan to try ketoconazole shampoo to address the issue and will consult a dermatologist.
A potential non-invasive topical treatment targeting the WNT Signaling Pathway for hair regeneration is being researched, with positive results on human hair follicle cells. Current effective treatments for hair loss include Minoxidil, finasteride, and hair transplantation.
Topical melatonin combined with minoxidil is being discussed for its potential benefits in hair growth. The conversation questions if it has effects similar to finasteride.
Latanoprost is discussed as a potential hair loss treatment, noted for its synergy with minoxidil and 5-AR inhibitors, but concerns include its effectiveness on scalp hair, cost, and potential skin darkening. Some users express interest in trying latanoprost or bimatoprost despite limited real-world evidence.
The conversation discusses potential hair loss treatments, including Setipiprant, Bimatoprost, and Follicept. The user encourages signing up for Follicept, which may come to market soon.
PP405 is anticipated as a future treatment for dormant hair follicles, but its effectiveness and safety are uncertain. Current treatments include oral minoxidil and microneedling, with some avoiding finasteride due to side effects.
Scientists discovered a potential baldness treatment from hairy moles, which can be injected like Botox. Users discussed the treatment's implications, including its safety and effectiveness.
The user reports some hair regrowth after two months of using 1.5mm microneedling with Minoxidil and Nizoral shampoo. They note reduced pain and skin flaking, attributing changes to skin thickening and collagen induction.
PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.
People are discussing the use of topical melatonin for hair loss and how often it should be applied, with one person noting it makes them groggy in the morning. They are inquiring about others' application frequency.
The conversation discusses adding melatonin powder to a topical finasteride solution for hair loss, with one reply suggesting that melatonin may promote faster hair growth but advising against mixing it directly into the solution due to potential instability.
The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.
Amplifica starting clinical trials for new hair loss drug. SCUBE3 protein discovered, stimulates hair growth, could be alternative to Minoxidil and Finasteride.
The user noticed hair thinning since age 15, initially attributed to a Vitamin D deficiency. They are currently using Rogaine and considering Propecia but are hesitant about a scalp biopsy; they seek financially practical treatments for male-pattern baldness.
TDM-105795 showed promising hair growth results, with higher efficacy than placebo and minimal side effects. It activates dormant hair follicle stem cells and may maintain gains without immediate loss, unlike minoxidil.
Adipose-derived stem cells with ATP improved hair regrowth in male and female mice with androgenetic alopecia. The most effective treatments were low dose stem cells with ATP for males and medium dose stem cells with non-liposomal ATP for females.
Chinese researchers have successfully created hair follicles in vitro, potentially offering unlimited hair for transplantation and a cure for hair loss. They plan to test these follicles in vivo on human scalps.
A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.
PP405 targets hair follicle stem cells differently than exercise-induced lactate, suggesting exercise alone may not replicate its benefits. Minoxidil and finasteride are recommended alongside exercise for hair regrowth, with additional suggestions like spicy food and infrared exposure.